

◆ Department of Continuing Medical Education ◆

**Conflict of Interest Disclosure and Resolution & Core Competencies**  
**Annual Advances and Innovations in Endoscopic Oncology**  
**and Multidisciplinary Gastrointestinal Cancer Care**  
**April 5 to 6, 2025**

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships<sup>1</sup> with any ineligible company<sup>2</sup>. To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

**CORE COMPETENCIES**

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Arya Amini, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Michelle A. Anderson, MD, MSc	Consultant for Boston Scientific.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	3 & 4
Sue Damico, AOCNP	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Vicki Doctor, MS, BSN	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4
Sarah Enslin, PA-C	I do not have any relevant financial relationships with any ineligible companies.	None	Planner 3, 5 & 6
Marwan Fakh, MD	Consultant for AbbVie, Adagene, Bayer, Bristol Myers Squibb, Delcath, Eisai, Entos, Janssen, Merck, Microbial Machines, Mirati, Nouscom, Pfizer, Roche/Genentech, Summit, Taiho, Tempus, and Totus.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Hannah Farfour, DNP, AGPCNP-BC	I do not have any relevant financial relationships with any ineligible companies.	None	Planner 2, 3, 5 & 6
Emre Gorgun, MD, MBA	Consultant for Boston Scientific, Dilumen, and Intuitive Surgical.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Stephen B. Gruber, MD, PhD	Grant/Research Support from AbbVie, AstraZeneca, Eisai, HaloDx, and Invitae.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 5
Maarouf A. Hoteit, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Jordan Iannuzzi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 6
Gregory Idos, MD, MS	Grant/Research Support from Adela.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	3 & 4
Toufic Kachaamy, MD	Consultant for Boston Scientific, Creo Medical, Cook Medical, Exact Sciences, Medtronic, Olympus, Pentax Medical, and Steris; On the Speakers Bureau for Grail; Other financial/material interests (Royalties) in Micro-Tech Endoscopy.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Moderator 1, 2, 3 & 4
Andreas M. Kaiser, MD	Consultant for Intuitive Surgical.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Moderator
Pashtoon Kasi, MD, MS	Consultant for Agenus, Astellas, AstraZeneca, Bayer, BostonGene, Daiichi Sankyo, Eli Lilly, Elicio Therapeutics, Foundation Medicine, Guardant Health, Illumina, Merck, Natera, Neogenomics, Regeneron, SAGA Diagnostics, SeaGen, Taiho, Tempus, and Xilio; Grant/Research Support from Agenus, Merck, and Novartis.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.  <i>Off-label use of liquid biopsies circulating tumor DNA - ctDNA and circulating tumor cells (CTCs).</i>	1, 2, 3 & 4
Vivek Kaul, MD	Consultant for Castle Biosciences, Cook Medical, Exact Sciences, Ironwood Pharma, Provation Medical, and Steris.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Moderator
Sameer Keole, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Jonathan Kessler, MD	Consultant for Boston Scientific, Ethicon, Galvanize Therapeutics, and Sirtex Medical	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 3 & 4
Ajaz M. Khan, MD, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Steven H. Lin, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
David Luyimbazi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Veeral M. Oza, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Rahul Pannala, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Mital Patel, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
N. Jewel Samadder, MD, MS	Consultant for Nouscom and Recursion Pharmaceuticals.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner 1, 2, 3, 4 & 5
Neil R. Sharma, MD	Consultant for Boston Scientific, Medtronic, Olympus, and Steris.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner 1, 2, 4 & 5
Gagandeep Singh, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Michael S. Smith, MD, MBA	Consultant for Steris Endoscopy.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2, 3, 4 & 5
Youssef Soliman, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Amar J. Thosani, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Cristian Tomasetti, PhD	Consultant for ProgomiQ; Other financial/material interests (Royalties) in Exact Sciences.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
V. Liana Tsikitis, MD, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4
DeAnna M. Weaver, CNP, MSN	I do not have any relevant financial relationships with any ineligible companies.	None	2, 4 & 5
Kun-Hsing Yu, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 3 & 4
Alvin M. Zfass, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist

1. The ACCME defines “‘relevant’ financial relationships” as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an “Ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients